Profile
Iris Good is the founder of UltraShape Ltd.
She is currently an investment committee member at Cambridge Enterprise Ltd., a trustee at Weizmann UK, and an advisor at Martlet Capital.
Iris Good active positions
Companies | Position | Start |
---|---|---|
Cambridge Enterprise Ltd.
Cambridge Enterprise Ltd. Investment ManagersFinance Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge. | Investment Committee Member | - |
UltraShape Ltd.
UltraShape Ltd. Medical SpecialtiesHealth Technology UltraShape redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for fat cell destruction and body sculpting. The company develops and markets clinically proven safe and effective solutions that enhance the lives of patients. The UltraShape proprietary technology employs pulsed (non-thermal) focused ultrasound that instantly, selectively and permanently destroys fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices in more than 50 countries, demonstrating safety and efficacy. The UltraShape Contour I system, is authorized for marketing outside the U.S. It is the first clinically proven non-invasive solution that offers measurable lasting body sculpting results for men and women with no need for maintenance treatments. The UltraShape system has been shown to be safe and effective in a multi-center controlled trial and numerous other peer-reviewed published independent clinical studies. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively destroy (breakdown) fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The latest Contour I V3 system uses Vertical Dynamic Focus™ (VDF) pulsed (non-thermal) focused ultrasound that instantly and permanently destroys fat cells providing patients a convenient noninvasive no-downtime solution to reduce localized fat deposits and body circumference. The UltraShape procedure is based on a natural fat clearance process where triglycerides and cell debris from the destroyed fat cells are processed by the body's natural physiological and metabolic pathways. These pathways are the same that handle fat during weight loss. Results from UltraShape's peer-reviewed published multi-center controlled clinical trial and other independent clinical studies show that the released triglycerides do not accumulate to a clinically significant extent in the blood or liver. Over 200,000 patient treatments have been performed worldwide with the Contour I showing high patient satisfaction while demonstrating safety and efficacy. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guides the operator through a pres-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of invasive and non-invasive procedures. The UltraShape procedure is performed during a convenient, 'walk-in, walk-out' session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S; the Contour Plus system is an investigational product limited by U.S. law to investigational use only. | Founder | - |
Martlet Capital
Martlet Capital Investment ManagersFinance Martlet Capital (Marlet Capital) is a venture capital subsidiary of Marshall of Cambridge (Holdings) Ltd founded in 2011 by Peter Lawton Cowley and Robert Marshall. The firm is headquartered in Cambridge, United Kingdom. | Consultant / Advisor | - |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Cambridge Enterprise Ltd.
Cambridge Enterprise Ltd. Investment ManagersFinance Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge. | Finance |
UltraShape Ltd.
UltraShape Ltd. Medical SpecialtiesHealth Technology UltraShape redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for fat cell destruction and body sculpting. The company develops and markets clinically proven safe and effective solutions that enhance the lives of patients. The UltraShape proprietary technology employs pulsed (non-thermal) focused ultrasound that instantly, selectively and permanently destroys fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices in more than 50 countries, demonstrating safety and efficacy. The UltraShape Contour I system, is authorized for marketing outside the U.S. It is the first clinically proven non-invasive solution that offers measurable lasting body sculpting results for men and women with no need for maintenance treatments. The UltraShape system has been shown to be safe and effective in a multi-center controlled trial and numerous other peer-reviewed published independent clinical studies. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively destroy (breakdown) fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The latest Contour I V3 system uses Vertical Dynamic Focus™ (VDF) pulsed (non-thermal) focused ultrasound that instantly and permanently destroys fat cells providing patients a convenient noninvasive no-downtime solution to reduce localized fat deposits and body circumference. The UltraShape procedure is based on a natural fat clearance process where triglycerides and cell debris from the destroyed fat cells are processed by the body's natural physiological and metabolic pathways. These pathways are the same that handle fat during weight loss. Results from UltraShape's peer-reviewed published multi-center controlled clinical trial and other independent clinical studies show that the released triglycerides do not accumulate to a clinically significant extent in the blood or liver. Over 200,000 patient treatments have been performed worldwide with the Contour I showing high patient satisfaction while demonstrating safety and efficacy. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guides the operator through a pres-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of invasive and non-invasive procedures. The UltraShape procedure is performed during a convenient, 'walk-in, walk-out' session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S; the Contour Plus system is an investigational product limited by U.S. law to investigational use only. | Health Technology |
Martlet Capital
Martlet Capital Investment ManagersFinance Martlet Capital (Marlet Capital) is a venture capital subsidiary of Marshall of Cambridge (Holdings) Ltd founded in 2011 by Peter Lawton Cowley and Robert Marshall. The firm is headquartered in Cambridge, United Kingdom. | Finance |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | Commercial Services |
- Stock Market
- Insiders
- Iris Good